Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam, Inc. (NASDAQ: BEAT) has established a Scientific Advisory Board (SAB) to enhance its medical studies and product development. The board will be chaired by C. Michael Gibson, an esteemed cardiologist known for his work in cardiovascular research. Dr. Gibson's extensive experience includes leading over 120 clinical trials and contributing to major cardiac drug approvals. This strategic move aims to bolster HeartBeam's proprietary ECG telemedicine technology, focusing on accurate heart attack diagnosis in ambulatory settings.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare company, announced its participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Key executives, including CEO Branislav Vajdic, will conduct video meetings during the event. The conference aims to showcase HeartBeam's innovative ECG telemedicine technology, designed to diagnose cardiovascular diseases effectively outside traditional medical settings. This breakthrough technology targets a significant market need, particularly in diagnosing heart attacks in high-risk patients.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed a $16.5 million IPO, selling 2,750,000 units at $6.00 each. The IPO generated net proceeds of $14.9 million, boosting the company’s cash balance to approximately $15.7 million. HeartBeam aims to advance its FDA-ready telemedicine solutions for cardiovascular assessment, with significant milestones set for 2022 and 2023. Q3 2021 financial results show an increased net loss of $1.2 million, up from $335,000 in Q3 2020, while R&D expenses rose to $105,000 from $57,000 year-over-year.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed its initial public offering of 2,750,000 units at $6.00 each, generating net proceeds of
HeartBeam, Inc. (NASDAQ: BEAT) has priced its initial public offering of 2,750,000 units at $6.00 per unit, consisting of one share of common stock and one warrant. The offering is expected to generate
Philips has announced its acquisition of BioTelemetry for USD 72.00 per share, totaling an implied enterprise value of USD 2.8 billion. This acquisition aligns with Philips' strategy to enhance healthcare delivery by combining its hospital monitoring capabilities with BioTelemetry’s strengths in remote cardiac diagnostics. BioTelemetry, which reported USD 439 million in sales in 2019, monitors over 1 million cardiac patients annually. The deal is anticipated to yield significant synergies and is expected to be accretive to Philips’ sales growth and adjusted EBITA margin beginning in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) reported a record quarterly revenue of $114.7 million for Q3 2020, marking a 3.0% year-over-year growth despite COVID-19 challenges. The company achieved a GAAP net income of $6.7 million (or $0.18 per diluted share), down from $8.3 million in Q3 2019. Adjusted net income was $16.5 million ($0.45 per diluted share). The gross profit was $69.0 million, representing 60.2% of total revenue. CEO Joseph H. Capper highlighted growth in all business segments and projected over 15% top-line growth in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on October 29 at 4:00 PM ET. Following this, an earnings conference call will take place at 5:00 PM ET, which will be available via webcast on the investor relations page of their website.
BioTelemetry specializes in remote medical technology, offering services that enhance health information accessibility and lower care costs. Their solutions include remote cardiac monitoring and clinical trial laboratory services.
BioTelemetry, Inc. (NASDAQ: BEAT) has acquired the On.Demand™ remote patient monitoring platform from Envolve People Care, a subsidiary of Centene Corporation. This acquisition enhances BioTelemetry's offerings for chronic care management, specifically targeting diabetes, hypertension, and chronic heart failure. The deal establishes BioTelemetry as the exclusive provider of diabetes RPM services to Centene's Medicaid members. The On.Demand platform aims to improve patient engagement and compliance while reducing healthcare costs through real-time monitoring and coaching.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
